Page last updated: 2024-11-07

umifenovir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

umifenovir: an antiviral agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131411
CHEMBL ID1214598
CHEBI ID134730
SCHEMBL ID1068701
MeSH IDM0230469

Synonyms (62)

Synonym
CHEMBL1214598
5674-91-9
arbidol ,
6-bromo-5-hydroxy-4-methylaminomethyl-1-methyl-2-benzenesulfenylmethylindole-3-ethyl carboxylate
ethyl 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
CHEMDIV1_000732
OPREA1_482224
OPREA1_384852
6-bromo-4-dimethylaminomethyl-5-hydroxy-1-methyl-2-phenylsulfanylmethyl-1h-indole-3-carboxylic acid ethyl ester
MLS000777586 ,
smr000413980
STK021887
ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1h-indole-3-carboxylate
CHEBI:134730
umifenovir
AKOS001485435
HMS589B06
AR-1I9514 ,
NCGC00246387-01
131707-25-0
1h-indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethyl ester
unii-93m09ww4ru
umifenovir [inn]
93m09ww4ru ,
HMS2760J21
NCGC00246387-02
1-methyl-2-((phenylthio)methyl)-3-carbethoxy-4-((dimethylamino)methyl)-5-hydroxy-6-bromindole
umifenovir [who-dd]
ethyl 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylsulfanyl)methyl)-1h-indole-3-carboxylate
SCHEMBL1068701
ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
ethyl 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-1h-indole-3-carboxylate
MLS006011808
umifenovir (inn)
D10558
6-bromo-4-dimethylaminomethyl-5-hydroxy-1-methyl-2-phenylsulfanylmethyl-1h-indole-3-carboxylic acid ethyl ester
6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]indole-3-carboxylic acid ethyl ester
ethyl 6-bromanyl-4-[(dimethylamino)methyl]-1-methyl-5-oxidanyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
cid_131411
6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-3-indolecarboxylic acid ethyl ester
bdbm83797
AB00644670_06
ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1h-indole-3-carboxylate
gtpl11089
AT13213
arbidol; umifenovir
75U ,
ethyl 6-bromo-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethylindole-3-carboxilate
KCFYEAOKVJSACF-UHFFFAOYSA-N
DTXSID60895015
DB13609
DT-0014
EX-A3050
1h-indole-3-carboxylic acid, 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-, ethyl ester
NCGC00246387-09
mfcd01326495
Q27271599
BCP04187
NCGC00246387-06
A888382
HY-14904
CS-0003625

Research Excerpts

Overview

Umifenovir (Arbidol) is an antiviral drug being used to treat influenza in Russia and China. It is a broad-spectrum antiviraldrug, with certain treatment effects on Coxsackie virus infection.

ExcerptReferenceRelevance
"Umifenovir (Arbidol®) is an antiviral drug being used to treat influenza in Russia and China."( Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Huang, J; Lian, N; Lin, Q; Lin, S; Xie, H; Zhao, J, 2020
)
2.72
"Umifenovir is an antiviral drug approved in China and Russia for the treatment of influenza. "( Intrinsic stability of the antiviral drug umifenovir by stress testing and DFT studies.
Antignac, M; Do, B; Sadou Yayé, H; Secretan, PH; Sogaldi, A; Thirion, O; Tortolano, L; Vieillard, V; Yagoubi, N, 2021
)
2.33
"Umifenovir (Arbidol) is an indole-derivative molecule, licensed in Russia and China for prophylaxis and treatment of influenza and other respiratory viral infections."( Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
Borisova, O; Faizuloev, E; Glubokova, E; Gracheva, A; Kartashova, N; Khamitov, R; Korchevaya, E; Leneva, I; Loginova, S; Poromov, A; Shchukina, V; Shtro, A, 2021
)
1.66
"Umifenovir is a broad-spectrum antiviral drug, with certain treatment effects on Coxsackie virus infection."( Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection.
Cui, J; Fan, Q; Huang, D; Li, H; Liang, C; Zhang, S; Zhi, C, 2017
)
2.62

Effects

ExcerptReferenceRelevance
"Umifenovir (Arbidol) has been reported to exhibit some degree of efficacy in multiple clinical trials for the treatment of COVID-19 as a monotherapy. "( Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.
Armen, RS; Freidel, MR, 2021
)
2.06

Treatment

Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss.

ExcerptReferenceRelevance
"The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice."( [Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
Falynskova, IN; Fedyakina, IT; Leneva, IA; Leonova, EI; Lepekha, LN; Makhmudova, NR; Mikhailova, NA; Osipova, EA; Zverev, VV, 2014
)
1.79
"Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss."( [Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
Falynskova, IN; Fedyakina, IT; Leneva, IA; Leonova, EI; Lepekha, LN; Makhmudova, NR; Mikhailova, NA; Osipova, EA; Zverev, VV, 2014
)
1.63

Toxicity

ExcerptReferenceRelevance
" Adverse events reported were similar in Arbidol group and in placebo group."( [Efficacy and safety of arbidol in treatment of naturally acquired influenza].
Cai, BQ; Gao, H; Li, LY; Lin, JT; Liu, L; Su, N; Wang, MZ; Yu, HX; Zhao, JZ, 2004
)
0.32
" The primary outcome will be clinical efficacy, and the secondary results will be accompanying symptoms, time for the temperature to return to normal, time of novel coronavirus nucleic acid turning negative, blood sample test, Computed Tomography examination, length of hospitalization, adverse reactions, and adverse events."( A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019.
Bao, S; Deng, Z; Sun, G; Wang, X; Xie, P; Zhao, M; Zhou, Y, 2020
)
0.56
"3%) in the arbidol group experienced adverse events during the follow-up period."( Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Cai, W; Chen, X; Deng, X; Guan, Y; Hong, W; Hu, F; Li, F; Li, L; Li, Y; Lin, W; Liu, J; Mo, X; Peng, P; Wang, J; Wang, Y; Wen, C; Xiao, G; Xie, Z; Zhang, F; Zhang, L, 2020
)
0.56
" It is efficacious, safe and well-tolerated at the tested dosage of 800mg BID, maximum 14 days."( Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.
Atam, V; Bhosale, V; Faridi, M; Fatima, J; Ghosh, N; Khan, H; Khan, ZA; Kundu, TK; Majumdar, N; Mishra, PR; Negi, MPS; Ramachandran, R; Rath, SK; Reddy, H; Sharma, S; Shukla, V; Singh, V; Srivastava, AK; Srivastava, M; Tripathi, CB; Tripathi, RK, 2022
)
0.93
" The primary endpoint was the time to normal body temperature, and the secondary endpoints included the time to remission of influenza symptoms, incidence of influenza-like complications, and incidence of adverse reactions."( Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.
Bai, X; Chen, G; Fan, X; Li, Y; Tian, Y; Wang, K; Wang, W; Xi, S; Zhao, Y, 2023
)
0.91
" Regarding the incidence of complications and adverse events, there was only one case of tracheitis, one case of nausea, one case of vomiting, and one case of dizziness in the control group."( Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.
Bai, X; Chen, G; Fan, X; Li, Y; Tian, Y; Wang, K; Wang, W; Xi, S; Zhao, Y, 2023
)
0.91
" Further, the patients treated with arbidol hydrochloride tablets had fewer adverse reactions, and thus, the tablets were safe to use."( Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.
Bai, X; Chen, G; Fan, X; Li, Y; Tian, Y; Wang, K; Wang, W; Xi, S; Zhao, Y, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The aim of this study was to compare the pharmacokinetic properties and tolerability, and to determine bioequivalence, of a newly developed generic dispersible tablet formulation (test) and a branded capsule formulation (reference) of arbidol 200 mg in healthy Chinese fasted male volunteers."( Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ; Yao, WF, 2009
)
0.35
" Several pharmacokinetic pararameters, including C(max), T(max), t((1/2)), AUC(0-t), and AUC(0-infinity), were determined from the plasma concentrations of the 2 formulations of arbidol using noncompartmental analysis."( Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ; Yao, WF, 2009
)
0.35
" The main pharmacokinetic properties with the test and reference formulations were as follows: C(max), 417."( Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ; Yao, WF, 2009
)
0.35
" Further investigations are needed to understand the importance of M6-1 in the efficacy and safety of arbidol, because of its high plasma exposure and long elimination half-life (25."( Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans.
Chen, X; Deng, P; Wang, T; Yu, K; Zhang, Y; Zhong, D, 2013
)
0.39
" Sex did not appear to affect the pharmacokinetic properties of arbidol."( Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers.
He, X; Li-Ling, J; Qiu, F; Su, X; Sun, Y; Zhao, L; Zhao, M; Zhu, X, 2013
)
0.39

Compound-Compound Interactions

To assess correlation of cytokines levels and therapy regimes. To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19.

ExcerptReferenceRelevance
"To study antiviral activity of arbidol in relation to various antigenic subtypes of influenza virus isolated from humans; efficacy of arbidol action in combination with adamantanic antiviral drugs, ribavirin and ribamidil on reproduction of influenza virus A (IVA) in cell culture."( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005
)
0.33
" The inhibiting activity of arbidolin on cell culture viral reproduction enhanced if arbidol was used in combination with amantadine, remantadin, ribavirin and ribamidil."( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005
)
0.33
"The antiviral drug combination consisting of arbidol and acetaminophen was investigated for its 4-week repeated oral administration in Sprague-Dawley rats."( A 4-week oral toxicity study of an antiviral drug combination consisting of arbidol and acetaminophen in rats.
Bai, WX; Liu, J; Pan, WN; Pan, YY; Shu, B; Wang, M; Yao, J, 2010
)
0.36
"To assess correlation of cytokines levels and therapy regimes a relationship of the time course of changes in the cytokines IFN-γ, IFN-α, IL-18, and TNF-α to the treatment option for influenza A (H1N1) pdm09 with umifenovir (Arbidol) 800 mg/day for 5 days (n=50); oseltamivir (Tamiflu) 150 mg/day for 5 days (n=50); umifenovir (Arbidol) 800 mg/day for 5 days in combination with Kagocel 72 mg/day for 2 days."( [Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel].
Dmitrenko, KA; Popov, AF; Shchelkanov, MY; Simakova, AI,
)
0.51
"This study aims to explore the clinical effect of Arbidol (ARB) combined with adjuvant therapy on patients with coronavirus disease 2019 (COVID-19)."( A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
Chen, W; Deng, M; Fang, Z; Lv, X; Wu, Z; Yao, M, 2020
)
0.56
"To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19."( Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
Chen, J; Lin, S; Niu, C; Xiao, Q, 2021
)
1.08
"A treatment regimen of Shufeng Jiedu Capsules combined with Arbidol to treat common-type COVID-19, combining traditional Chinese and western allopathic medicine, improves time to recovery, has better clinical effectiveness, and is safe."( Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
Chen, J; Lin, S; Niu, C; Xiao, Q, 2021
)
0.86
"Arbidol combined with LH treatment may be more effective in improving the prognosis and accelerating the SARS-CoV-2 clearance in patients with COVID-19."( Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
Chen, C; Li, C; Li, X; Liu, L; Shi, F; Tu, P; Zhang, M, 2021
)
0.62
"This study aimed to evaluate the antiviral efficacy of lopinavir-ritonavir alone or combined with arbidol in the treatment of hospitalized patients with common coronavirus disease-19 (COVID-19)."( Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan, X; Shao, C; Wu, Z; Xu, Y; Zeng, X, 2021
)
0.62
"No benefit was observed in the antiviral effect of lopinavir-ritonavir combined with arbidol compared with lopinavir-ritonavir alone in the hospitalized patients with COVID-19."( Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan, X; Shao, C; Wu, Z; Xu, Y; Zeng, X, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"In healthy Chinese subjects, single dosing of arbidol resulted in linear plasma pharmacokinetics."( Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers.
He, X; Li-Ling, J; Qiu, F; Su, X; Sun, Y; Zhao, L; Zhao, M; Zhu, X, 2013
)
0.39
" Patients were randomized into two groups: a group of patients (therapy group) treated by Arbidol (umifenovir) at a dosage of 800 mg/day (2 capsules) for 5 days (n=181), and a group of patients receiving placebo 4 times a day for 5 days (n=178)."( Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR).
Bulgakova, VA; Grekova, AI; Leneva, IA; Lvov, NI; Maleev, VV; Poromov, AA; Pshenichnaya, NY; Selkova, EP; Shestakova, IV, 2019
)
1.05
" The available dosage form consists of capsules marketed under the brand name Arbidol®."( Intrinsic stability of the antiviral drug umifenovir by stress testing and DFT studies.
Antignac, M; Do, B; Sadou Yayé, H; Secretan, PH; Sogaldi, A; Thirion, O; Tortolano, L; Vieillard, V; Yagoubi, N, 2021
)
0.89
" It is efficacious, safe and well-tolerated at the tested dosage of 800mg BID, maximum 14 days."( Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.
Atam, V; Bhosale, V; Faridi, M; Fatima, J; Ghosh, N; Khan, H; Khan, ZA; Kundu, TK; Majumdar, N; Mishra, PR; Negi, MPS; Ramachandran, R; Rath, SK; Reddy, H; Sharma, S; Shukla, V; Singh, V; Srivastava, AK; Srivastava, M; Tripathi, CB; Tripathi, RK, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolyl carboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency39.81070.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency17.58860.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency11.22020.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency28.18380.707912.194339.8107AID720542
EWS/FLI fusion proteinHomo sapiens (human)Potency18.56220.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency8.91250.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency18.35640.004611.374133.4983AID624297
Glycoprotein hormones alpha chainHomo sapiens (human)Potency28.18384.46688.344810.0000AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular regionHemagglutininInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneHemagglutininInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
virion membraneHemagglutininInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1364917Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by neutral red staining-based microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1330327Antiviral activity against Chikungunya virus 899 pseudoparticles infected in African green monkey BGM cells assessed as inhibition of pseudoparticles entry after 72 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1487672Binding affinity to Influenza A virus (A/Puerto Rico/8/1934(H1N1)) PR8 hemagglutinin-1 by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID499260Antiviral activity against HCV 2a infected in human Huh7.5 cells assessed inhibition of viral replication after 3 days by luciferase assay2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
AID1280381Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 0.625 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1364916Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 18 hrs by neutral red staining-based microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1660631Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1756955Cytotoxicity against dog MDCK cells incubated for 48 hrs by MTT assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Antiviral Bafilomycins from a Feces-Inhabiting
AID1364918Antiviral activity against Chikungunya virus LR2006 OPY1 infected in human MRC5 cells after 48 hrs by indirect immunofluorescence analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1660634Selectivity index, ratio of CC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by crystal violet staining based assay to IC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incu2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID497421Antiviral activity against HCV 2a infected in human Huh7.5 cells assessed inhibition of viral entry after 3 days2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
AID1280378Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 5 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1330328Cytotoxicity against African green monkey BGM cells2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1660700Binding affinity to Influenza A virus (A/Aichi/2/1968(H3N2)) Hemagglutinin at 1.5625 to 50 uM by SPR assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1660699Binding affinity to Influenza A virus (A/California/04/2009(H1N1)) Hemagglutinin at 1.5625 to 50 uM by SPR assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1280379Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 2.5 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1487667Binding affinity to Influenza A virus (A/Hong Kong/1/1968(H3N2)) PR8 hemagglutinin-3 assessed as dissociation constant after 180 secs by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID1330330Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero A cells assessed as inhibition of viral replication by measuring reduction in intracellular viral RNA treated 2 hrs prior to infection measured after 24 hrs by qRT-PCR 2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1364922Selectivity index, ratio of CC50 for human MRC5 cells to IC50 for Chikungunya virus LR2006 OPY12017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1487669Binding affinity to Influenza A virus (A/Puerto Rico/8/1934(H1N1)) PR8 hemagglutinin-1 assessed as dissociation constant after 180 secs by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID1200502Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 1.25 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1200498Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 20 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1200493Binding affinity to influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1487668Binding affinity to Influenza A virus (A/Hong Kong/1/1968(H3N2)) PR8 hemagglutinin-3 assessed as association constant after 180 secs by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID581112Inhibition of STAT3 in human HeLa cells at 5 uM after 24 hrs by luciferase reporter gene assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.
AID1280380Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 1.25 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1200500Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 5 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1364919Antiviral activity against Chikungunya virus LR2006 OPY1 infected in human MRC5 cells after 30 mins by indirect immunofluorescence analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1364920Antiviral activity against Chikungunya virus LR2006 OPY1 infected in human MRC5 cells after 60 mins by indirect immunofluorescence analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1756954Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells pre-treated with virus for 30 mins followed by cell infection for 1 hr by MTT assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Antiviral Bafilomycins from a Feces-Inhabiting
AID1487671Binding affinity to Influenza A virus (A/Hong Kong/1/1968(H3N2)) PR8 hemagglutinin-3 by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID497424Selectivity index, IC50 for human Huh7.5 cells to TC50 for inhibition of HCV 2a entry into human Huh7.5 cells2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
AID1650133Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1660698Binding affinity to Influenza A virus (A/Puerto Rico/8/1934(H1N1)) Hemagglutinin at 1.5625 to 50 uM by SPR assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1330332Antiviral activity against Chikungunya virus assessed as inhibition of virus replication by cell based assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1280360Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor by surface plasmon resonance assay (Rvb = 70 nM)2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1330321Cytotoxicity against African green monkey Vero cells assessed as reduction in metabolic activity by MTS/PMS based microscopic analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1330322Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for Chikungunya virus 899 infected in African green monkey Vero cells2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID499262Selectivity index, IC50 for human Huh7.5 cells to TC50 for inhibition of HCV 2a replication in human Huh7.5 cells2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
AID1280377Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 10 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1650131Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic 2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1330326Antiviral activity against Sindbis virus infected in African green monkey Vero A cells assessed as inhibition of virus-induced cytopathogenic effect measured 5 days post infection by MTS/PMS based microscopic analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1200503Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 0.625 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1280376Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor at 20 uM by surface plasmon resonance assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1487670Binding affinity to Influenza A virus (A/Puerto Rico/8/1934(H1N1)) PR8 hemagglutinin-1 assessed as association constant after 180 secs by biolayer interferometry analysis2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.
AID1330320Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect measured 5 days post infection by MTS/PMS based microscopic analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1280383Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor by measuring dissociation constant by surface plasmon resonance assay (Rvb = 0.001473/Ms)2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1200499Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 10 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1280382Binding affinity to Influenza A virus A/WSN/33 (H1N1) HA1 protein assessed as decrease in protein affinity to sialic acid receptor by measuring association constant by surface plasmon resonance assay (Rvb = 20810/s)2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1330325Antiviral activity against Semliki forest virus infected in African green monkey Vero A cells assessed as inhibition of virus-induced cytopathogenic effect measured 5 days post infection by MTS/PMS based microscopic analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1364921Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus LR2006 OPY12017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1756953Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells incubated for 48 hrs by MTT assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Antiviral Bafilomycins from a Feces-Inhabiting
AID497423Cytotoxicity against human Huh7.5 cells by celltiter-blue viability assay2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
AID1073347Antiviral activity against Chikungunya virus by cell-based assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.
AID1650132Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1200501Inhibition of influenza A virus A/WSN/33 (H1N1) Hemagglutinin 1 binding to sialic acid receptor assessed as response unit at 2.5 ug/ml by surface plasmon resonance assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1330331Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero A cells assessed as inhibition of viral replication at post entry step by measuring reduction in intracellular viral RNA treated 2 hrs post infection measured after 24 2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (213)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (3.29)18.2507
2000's22 (10.33)29.6817
2010's64 (30.05)24.3611
2020's120 (56.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.57 (24.57)
Research Supply Index5.55 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index68.60 (26.88)
Search Engine Supply Index1.96 (0.95)

This Compound (45.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (9.83%)5.53%
Reviews35 (14.96%)6.00%
Case Studies13 (5.56%)4.05%
Observational8 (3.42%)0.25%
Other155 (66.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]